Perceptive Pharma Research | Richmond, TX
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The primary objective is to characterize the efficacy TEV-48574 in adult participants with IBD (moderate to severe Ulcerative Colitis (UC) or Crohn's Disease (CD)) as assessed by induction of clinical remission (UC) and endoscopic response (CD) at week 14.
Secondary objectives:
The study will consist of a screening period of up to 6 weeks (42 days), a 14-week treatment period, and a 4-week follow-up period.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
NOTE- Additional criteria apply, please contact the investigator for more information
Exclusion criteria
NOTE- Additional criteria apply, please contact the investigator for more information
Primary purpose
Allocation
Interventional model
Masking
240 participants in 6 patient groups, including a placebo group
Loading...
Central trial contact
Teva U.S. Medical Information
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal